Specifically, PD‐L1 inhibitors, including a locally expressed PD‐L1 trap delivered by lipid–protamine–DNA nanoparticles, hold the potential to improve cancer treatment index following oxaliplatin‐based chemotherapy (Song et al., 2018). This evidence concerns the gene CD274 and cancer.